Abstract library

225 results for "de Jonge-Muller".
#16 Endoglin as indicator of metastatic neuroendocrine tumors of the pancreas
Introduction: Neuroendocrine tumors of the pancreas are rare, highly vascularized tumors. Endoglin, a Transforming Growth Factor-β co-receptor, is a marker for angiogenic endothelial cells. Angiogenesis is required for tumor progression and the development of metastases. Recently, endoglin expression was found to be a prognostic marker in pancreatic carcinomas. However, the role of endoglin in neuroendocrine pancreatic tumors has so far not been studied.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Patricia Kuiper
#1828 5-Fluorouracile Plus Dacarbazine in Metastatic Digestive Neuroendoendocrine Tumors: Efficacy and Potential Biomarkers
Introduction: The 5-fluorouracile (5FU) + dacarbazine (DTIC) combination has been poorly evaluated in NET
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Dr Louis de Mestier
#1901 Portal Hypertension-Related Digestive Hemorrhage in Patients with Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (pNET) can cause portal hypertension (PHT)
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Nelly Muller
#1329 The MEN2B Due to de Novo Mutation M918T at Algiers
Introduction: The MEN2B, or Gorlin syndrome is a very rare disorder where there are a medullary cancer of thyroide associated with pheochromocytoma and other clinical signs such as a ganglion – neuromatose or a Marfan syndrome. The MEN2B belongs MEN2 are rare hereditary disease, transmitted as an autosomal dominant mutations linked to the RET proto-oncogene.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Professor Chikouche Ammar
Authors: Chikouche A, ...
#1884 Towards Optimal Personalized Diet and Vitamin Supplementation in NET Patients; A Feasibility Study
Introduction: Patients with a neuroendocrine tumor (NET) often have gastro-intestinal complaints due to somatostatin analogue (SSA), tumor mass, secretion of neuroendocrine amines or treatment. This can lead to impaired absorption of critical food components such as vitamins. Serotonin producing NET patients may also have low plasma tryptophan.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: drs Ld de Hosson
#1885 Web-Based Tailored Information and Support for Patients with a Neuroendocrine Tumor
Introduction: Patients with a neuroendocrine tumour (NET) frequently experience physical and psychosocial complaints. Novel strategies to provide information to optimize supportive care in these patients are of interest.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: drs Ld de Hosson
#2159 Hepatic Steatosis Secondary to Peptide Receptor Radionuclide Therapy with Somatostatin Analogue
Introduction: Peptide Receptor Radionuclide Therapy (PRRT) with 177-Lutetium-DOTA-TATE is a therapeutic modality for neuroendocrine tumors. It has some well known side effects, concerning specially the bone marrow (from cytopenias to myelodysplastic syndrome), in addition to mild renal effects. Hepatotoxicity from PRRT is still being studied.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: MD Beatriz Arruda Matheos de Lima
#269 Expression of IGF/mTOR Pathway Components in Human Pheochromocytomas and In Vitro Inhibition of PC12 Rat Pheochromocytoma Cell Growth by mTOR Inhibitors
Introduction: The pathogenesis of pheochromocytomas (pheo) is poorly understood and malignant pheo need new treatment options. mTOR inhibitors, as sirolimus(S) and everolimus(E), are promising antineoplastic drugs.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: MD Maria Cristina De Martino
#670 The Relationship Between the Ki-67 Protein and IGF-Related Genes in Gastroenteropancreatic Neuroendocrine Tumor Patients with Normal and Elevated Serum Chromogranin-A
Introduction: GEP-NETs are rare, heterogeneous neoplasms with a distinct biological and clinical behavior. Both IGF-system and Ki-67 indices have been reported as important stimulating factors in carcinogenesis and/or tumor progression. The tumor marker CgA is an independent predictor for survival as well. Currently no data are available about a possible interaction between IGF-system (IGF(-R)s, IRs, BPs) and Ki-67 protein in GEP-NET patients with normal and elevated serum CgA.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Drs Roxanne Van Adrichem
Keywords: GEP-NET
#850 Expression of IGF/mTOR Pathway Components in Human Pheochromocytomas and In Vitro Inhibition of PC12 rat Pheochromocytoma Cell Growth by mTOR Inhibitors alone and in Combination with the Dual IGFI-R/INS-R Antagonist OSI-906
Introduction: Dysregulation of the mTOR and IGF pathways have been suggested to be involved in the pathogenesis of pheochromocytomas (PCC). mTOR inhibitors, such as sirolimus (S) and everolimus (E), as well as IGFI-R antagonists such as OSI-906, could be new a treatment for malignant PPC.
Conference: 11th Annual ENETS Conference (2014)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Maria Cristina De Martino
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.